{"id":905149,"date":"2025-11-04T13:16:01","date_gmt":"2025-11-04T18:16:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/"},"modified":"2025-11-04T13:16:01","modified_gmt":"2025-11-04T18:16:01","slug":"aligos-therapeutics-to-present-at-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/","title":{"rendered":"Aligos Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Nov.  04, 2025  (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences.<\/p>\n<p>\n        <strong><br \/>\n          <u>Jefferies London Healthcare Conference<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT<\/li>\n<\/ul>\n<p>\n        <strong><br \/>\n          <u>Piper Sandler 37<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>th<\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u> Annual Healthcare Conference<\/u><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Fireside Chat on Wednesday, December 3, 2025 at 2:00pm ET<\/li>\n<\/ul>\n<p>The presentations will premiere at the time listed above and can be accessible by visiting the Presentation &amp; Events section on the \u201cInvestors\u201d page of Aligos\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NqTAiIhDMdjWT64fSA7VhL22SYRGz870ZtmtnzA3QXb15cIys0IV4hDQ6_0QTwAUYviquwIes4H2sAUsnFZc1g==\" rel=\"nofollow\" target=\"_blank\">www.aligos.com<\/a>. A replay of the webcast will be available following the presentation for at least 30 days.<\/p>\n<p>\n        <strong>About Aligos<\/strong>\n      <\/p>\n<p>Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&amp;D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.<\/p>\n<p>For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NqTAiIhDMdjWT64fSA7VhEW26AYmP6HFPX7edsyFqOMu4foBgOmcffhoWfHDMJy2pJrxenzhsC1zxJwjD1Jpog==\" rel=\"nofollow\" target=\"_blank\">www.aligos.com<\/a> or follow us on LinkedIn or X.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered \u201cforward-looking statements,\u201d including without limitation, statements regarding Aligos\u2019 financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos\u2019 clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos\u2019 capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos\u2019 Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.\u00a0\u00a0 <br \/>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><strong>Aligos Therapeutics<\/strong><\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Jordyn Tarazi<br \/>Vice President, Investor Relations &amp; Corporate Communications<br \/>+1 (650) 910-0427<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=H-LUXIOVINgpSu3EVddNPc_0YnlTYHrW8KGYiW-w2plLobdYPeBbAAgziIWQJ4tkbMOzORtWctDjFWLDscJmIlhR3XoQIkQ6oephEsYr6U4=\" rel=\"nofollow\" target=\"_blank\">jtarazi@aligos.com<\/a><\/p>\n<p>\n        <strong>Media Contact<\/strong><br \/>\n        <br \/>Inizio Evoke<br \/>Jake Robison<br \/>Vice President<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8T04vog3LpWZ0XfJdv2-IprArKeArZjJ5FoqYthJg-K-1zweNnWJA0BIssO_IqKNSQZQTbB0FNTmBi875dI7XeOXycwgrjyPUQ7EUbhyHcn7Ae_82tMPnHVPM3pH9wG\" rel=\"nofollow\" target=\"_blank\">Jake.Robison@inzioevoke.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWUzYjFjYWEtZTg5Yi00ZmRlLWE1NGMtMWRkODViYmQ1ODRjLTEyMTU0NjktMjAyNS0xMS0wNC1lbg==\/tiny\/Aligos-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences. Jefferies London Healthcare Conference Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT Piper Sandler 37 th Annual Healthcare Conference Fireside Chat on Wednesday, December 3, 2025 at 2:00pm ET The presentations will premiere at the time listed above and can be accessible by visiting the Presentation &amp; Events section on the \u201cInvestors\u201d page of Aligos\u2019 website at www.aligos.com. A replay of the webcast will be available following the presentation for at least &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aligos Therapeutics to Present at Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905149","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences. Jefferies London Healthcare Conference Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT Piper Sandler 37 th Annual Healthcare Conference Fireside Chat on Wednesday, December 3, 2025 at 2:00pm ET The presentations will premiere at the time listed above and can be accessible by visiting the Presentation &amp; Events section on the \u201cInvestors\u201d page of Aligos\u2019 website at www.aligos.com. A replay of the webcast will be available following the presentation for at least &hellip; Continue reading &quot;Aligos Therapeutics to Present at Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T18:16:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aligos Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2025-11-04T18:16:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"},\"wordCount\":484,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/\",\"name\":\"Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\",\"datePublished\":\"2025-11-04T18:16:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aligos Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences. Jefferies London Healthcare Conference Fireside Chat on Monday, November 17, 2025 at 3:00pm GMT Piper Sandler 37 th Annual Healthcare Conference Fireside Chat on Wednesday, December 3, 2025 at 2:00pm ET The presentations will premiere at the time listed above and can be accessible by visiting the Presentation &amp; Events section on the \u201cInvestors\u201d page of Aligos\u2019 website at www.aligos.com. A replay of the webcast will be available following the presentation for at least &hellip; Continue reading \"Aligos Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T18:16:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aligos Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2025-11-04T18:16:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/"},"wordCount":484,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/","name":"Aligos Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=","datePublished":"2025-11-04T18:16:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzk5MyM3MjQyMDc0IzIyMDM5MTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aligos-therapeutics-to-present-at-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aligos Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905149","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905149"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905149\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}